Scarica l'app Stockscreener
9.62
0.57%
0.05
Precedente Chiudi:
$9.57
Aprire:
$9.68
Volume 24 ore:
59,160
Relative Volume:
0.06
Capitalizzazione di mercato:
$620.26M
Reddito:
$202.09M
Utile/perdita netta:
$-61.69M
Rapporto P/E:
-8.9074
EPS:
-1.08
Flusso di cassa netto:
$-35.64M
1 W Prestazione:
+4.62%
1M Prestazione:
+2.61%
6M Prestazione:
-31.35%
1 anno Prestazione:
-23.55%
Intervallo 1D:
$9.52
$9.734
Intervallo di 1 settimana:
$9.1212
$9.734
Portata 52W:
$8.67
$17.82
Evolus Inc Stock (EOLS) Company Profile
Nome
Evolus Inc
Settore
Telefono
(949) 284-4555
Indirizzo
520 NEWPORT CENTER DRIVE, NEWPORT BEACH
Confronta EOLS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EOLS
Evolus Inc
|
9.62 | 597.69M | 202.09M | -61.69M | -35.64M | -1.08 |
|
ZTS
Zoetis Inc
|
152.20 | 68.05B | 9.29B | 2.52B | 2.28B | 5.57 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.73 | 46.58B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
HLN
Haleon Plc Adr
|
9.7418 | 43.71B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.59 | 18.40B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
302.00 | 13.23B | 2.99B | 1.21B | 1.13B | 25.06 |
Evolus Inc Stock (EOLS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-17 | Iniziato | BTIG Research | Buy |
| 2024-01-29 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2022-06-23 | Iniziato | Needham | Buy |
| 2022-05-12 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-01-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-04-08 | Reiterato | H.C. Wainwright | Buy |
| 2021-02-24 | Downgrade | Truist | Buy → Hold |
| 2020-07-07 | Downgrade | Mizuho | Buy → Neutral |
| 2020-02-06 | Ripresa | Mizuho | Buy |
| 2019-11-26 | Iniziato | SVB Leerink | Outperform |
| 2019-09-05 | Ripresa | Mizuho | Buy |
| 2019-06-28 | Iniziato | Wells Fargo | Market Perform |
| 2019-06-11 | Iniziato | Barclays | Underweight |
| 2019-03-20 | Iniziato | SunTrust | Buy |
| 2019-02-14 | Iniziato | H.C. Wainwright | Buy |
| 2019-01-29 | Iniziato | Stifel | Buy |
Mostra tutto
Evolus Inc Borsa (EOLS) Ultime notizie
What analysts say about Evolus Inc. stockExtraordinary profit generation - Autocar Professional
Evolus to Report Second Quarter Financial Results on August 5, 2025 - BioSpace
Evolus Inc. Stock Analysis and ForecastDynamic investment opportunities - jammulinksnews.com
Is Evolus Inc. a good long term investmentFree Risk Assessment Services - Autocar Professional
What drives Evolus Inc. stock priceFree Predictions - Autocar Professional
EvolusA Slightly Risky Buy Ahead Of Q2 Earnings (NASDAQ:EOLS) - Seeking Alpha
Midday Stock Roundup: loanDepot Up 10% with High Volume - Orange County Business Journal
How Evolus Inc. stock performs during market volatilityInsider Level Guidance - Newser
What makes Evolus Inc. stock price move sharplyTop Analyst Picks - Newser
Why Evolus Inc. stock attracts strong analyst attentionRisk Controlled Trading Ideas - Newser
Evolus announces inducement grants - Medical Buyer
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 - BioSpace
How reliable are EOLS's earnings forecasts historically? - AInvest
Is EOLS's Q1 2025 earnings forecast optimistic? - AInvest
Evolus Expands into French Market - Orange County Business Journal
EOLS Partners with Symatese for Nuceiva Distribution in France | - GuruFocus
Fastest-Growing Botox Alternative Nuceiva Enters French Beauty Market Through Strategic Partnership - Stock Titan
Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in France - Yahoo Finance
Trade Alert: President Of Evolus David Moatazedi Has Sold Stock - simplywall.st
Where are the Opportunities in (EOLS) - news.stocktradersdaily.com
When Can We Expect A Profit From Evolus, Inc. (NASDAQ:EOLS)? - Yahoo Finance
Evolus (NASDAQ:EOLS) Shares Down 5.5% on Insider Selling - Defense World
(EOLS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | EOLS Stock News - GuruFocus
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Mizuho Securities Reaffirms Their Buy Rating on Evolus (EOLS) - The Globe and Mail
Evolus Inc (EOLS) Stock Price Up 3.95% on Jun 11 - GuruFocus
Insider Spends US$189k Buying More Shares In Evolus - simplywall.st
Evolus Inc Azioni (EOLS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.26%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):